Step 1 topics → Neurology and Special Senses → NMJ Disorders (Myasthenia, LEMS, Botulinum)

NMJ Disorders (Myasthenia, LEMS, Botulinum)

USMLE Step 1 trap: Confuses the response to repeated muscle use in MG versus LEMS. Myasthenia gravis worsens with repeated use (fatigable weakness), while LEMS transiently improves with repeated use due to facilitated ACh release.

NMJ disorders are a high-yield cluster on USMLE Step 1 because they test your ability to distinguish three conditions that all cause weakness but through completely different mechanisms. Myasthenia gravis (MG), Lambert-Eaton myasthenic syndrome (LEMS), and botulism each hit a different part of the neuromuscular junction — postsynaptic, presynaptic, and presynaptic respectively — and the exam exploits that overlap aggressively. You need to know not just what each disease does, but why it does it, so you can handle a novel clinical vignette rather than just a list of buzzwords.

The exam tests this from multiple angles: pure recall (what antibody does MG target?), clinical application (why does strength improve briefly in LEMS but not MG with repeated use?), and passage-based reasoning (given EMG findings showing an incremental response, what's the diagnosis and paraneoplastic association?). The tricky part is that all three cause fatigable weakness and cranial nerve involvement, so surface-level memorization fails quickly. USMLE Step 1 loves to embed a critical distinguishing feature — like the response to repeated stimulation or the clinical setting of small cell lung cancer — in a long vignette and see if you catch it.

The biggest pitfalls are conflating pre- vs. postsynaptic pathology in MG and LEMS, assuming both worsen with use, and blurring botulinum toxin's mechanism with tetanus toxin. These aren't random errors — they come from students memorizing disease names without building a mechanistic model. Once you anchor everything to where in the NMJ the problem lives and what happens to ACh signaling, the clinical features and treatment strategies follow logically.

From real student decks
95%have cards covering this topic
78%have mature cards
1median lapses in 14 days

Well-covered in most decks — the challenge is retention, not exposure.

Common misconceptions

Common mistake
Wrong: Both myasthenia gravis and LEMS worsen with repeated muscle use.
Right: Myasthenia gravis worsens with repeated use (fatigable weakness), while LEMS transiently improves with repeated use due to facilitated ACh release.
In MG, the postsynaptic ACh receptors are destroyed or blocked, so each successive nerve impulse has fewer receptors to activate — weakness accumulates with use, and the EMG shows a decremental response. In LEMS, the presynaptic VGCC are blocked, limiting calcium entry and ACh release at rest; with repeated stimulation, calcium builds up in the terminal and ACh release transiently increases, causing brief strength improvement and an incremental EMG response. This is a core distinguishing feature USMLE Step 1 tests directly — don't flatten both into 'weakness with use.'
Common mistake
Wrong: Myasthenia gravis antibodies block ACh release from the presynaptic terminal.
Right: MG antibodies target postsynaptic nicotinic ACh receptors (or MuSK), reducing receptor availability rather than blocking presynaptic release.
MG is a postsynaptic disease. Anti-AChR antibodies (or anti-MuSK antibodies in seronegative cases) bind and destroy nicotinic receptors on the muscle end plate, reducing the total number of functional receptors. The presynaptic terminal releases ACh normally — there's just nowhere adequate for it to bind. This is why pyridostigmine (an acetylcholinesterase inhibitor that increases synaptic ACh) helps: it makes the most of what little receptor availability remains. Confusing this with presynaptic blockade leads to wrong treatment logic and wrong EMG interpretation.
Common mistake
Wrong: Botulinum toxin permanently destroys the NMJ, similar to tetanus toxin's mechanism.
Right: Botulinum toxin cleaves SNARE proteins to irreversibly block ACh vesicle fusion at that terminal, but recovery occurs via sprouting of new nerve terminals; tetanus toxin blocks inhibitory interneurons centrally.
Botulinum toxin cleaves SNARE proteins (specifically SNAP-25, synaptobrevin, or syntaxin depending on the serotype), permanently disabling vesicle fusion at that nerve terminal — ACh cannot be released. However, the neuron itself is intact and can sprout new terminals over weeks to months, which is how recovery happens. Tetanus toxin, by contrast, is taken up retrogradely into inhibitory interneurons in the spinal cord and brainstem, where it blocks glycine and GABA release — this disinhibits motor neurons, causing the spastic, lockjaw presentation. Same family of toxin, completely opposite clinical syndrome because the site of action is entirely different.
Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →
Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

  1. Know the antibody target in myasthenia gravis (postsynaptic nicotinic ACh receptors or MuSK), how to diagnose it (edrophonium/Tensilon test, anti-AChR antibodies, EMG decremental response), how it presents (fatigable ptosis, diplopia, proximal weakness worse with activity), and how to treat it (pyridostigmine, thymectomy if thymoma present, immunosuppression).
  2. Know the antibody target in LEMS (presynaptic voltage-gated calcium channels, VGCC), understand why weakness transiently improves with repeated use (calcium accumulates, more ACh released), recognize the paraneoplastic link to small cell lung cancer, and distinguish the incremental EMG response of LEMS from the decremental response of MG.
  3. Know that botulinum toxin cleaves SNARE proteins to block ACh vesicle fusion at the presynaptic terminal, causing descending flaccid paralysis with autonomic involvement; know that recovery requires sprouting of new nerve terminals; and contrast this with tetanus toxin, which travels retrogradely to block inhibitory interneurons centrally, causing spastic paralysis rather than flaccid paralysis.

Can you avoid these mistakes?

A 55-year-old man with a 30-pack-year smoking history presents with proximal leg weakness that actually improves after he walks around for a minute, along with dry mouth and constipation. Reflexes are diminished. What is the diagnosis, what antibody is responsible, and what cancer must you rule out?
You give edrophonium to a patient with ptosis and diplopia and her symptoms transiently resolve. Explain the mechanism of why this works — and why this test would NOT be useful for distinguishing MG from LEMS.
A 6-month-old infant presents with hypotonia, poor feeding, weak cry, and constipation after the parents started feeding her honey. Cranial nerves are involved first. What toxin is responsible, what is its molecular mechanism, and why does the baby eventually recover even though the toxin's effect on each terminal is irreversible?
On EMG, one patient shows a decremental response to repetitive nerve stimulation and another shows an incremental response. Which pattern goes with which disease, and what does each pattern tell you about where the defect is — presynaptic or postsynaptic?

Related topics

Synaptic Transmission and Neurotransmitters Neural Tube Formation and Derivatives Neural Crest Derivatives Neural Tube Defects Other Developmental Malformations

See how your Anki deck covers this topic.

Upload your deck for a free audit →